Pharmacotherapy for obesity: A field in crisis?

Expert Review of Endocrinology and Metabolism

Volumn 6, Issue 4, 2011, Pages 563-577

  Fenske, Wiebke ^a   Parker, Jennifer ^a   Bloom, Stephen R ^a  

^a IMPERIAL COLLEGE LONDON   (United Kingdom)

Author keywords

analog; anorectic; anti obesity drugs; GLP 1; gut hormones; obesity

Indexed keywords

AMFEBUTAMONE; AMFEBUTAMONE PLUS NALTREXONE; CANNABINOID RECEPTOR ANTAGONIST; DEXFENFLURAMINE; EXENDIN 4; FENFLURAMINE; GLUCAGON LIKE PEPTIDE 1 RECEPTOR; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE KINASE; LIRAGLUTIDE; MELANOCORTIN 4 RECEPTOR; MELANOCORTIN RECEPTOR AGONIST; MK 0493; MK 0557; NEUROPEPTIDE; NEUROPEPTIDE Y RECEPTOR ANTAGONIST; OTENABANT; PHENTERMINE PLUS TOPIRAMATE; PLACEBO; PRAMLINTIDE; RIMONABANT; RM 493; SEROTONIN 2C AGONIST; SEROTONIN 2C RECEPTOR; SEROTONIN AGONIST; SEROTONIN ANTAGONIST; SIBUTRAMINE; TESOFENSINE; TETRAHYDROLIPSTATIN; UNCLASSIFIED DRUG; UNINDEXED DRUG; ZONISAMIDE;

ABDOMINAL PAIN; BLOATING; COMBINATION CHEMOTHERAPY; DIARRHEA; DIET; DROWSINESS; DRUG DOSE ESCALATION; DRUG EFFICACY; DRUG SAFETY; DRUG WITHDRAWAL; DYSPEPSIA; ENERGY BALANCE; ENERGY EXPENDITURE; EXERCISE; FATIGUE; FLATULENCE; FOOD INTAKE; HOMEOSTASIS; HUMAN; LIVER INJURY; METABOLIC SYNDROME X; MONOTHERAPY; NAUSEA; NONHUMAN; OBESITY; PRIORITY JOURNAL; REVIEW; SEROTONINERGIC SYSTEM; SPEECH DISORDER; WEIGHT REDUCTION;

EID: 79960153207     PISSN: 17446651     EISSN: 17448417     Source Type: Journal    
DOI: 10.1586/eem.11.50     Document Type: Review

References (177)

1. Mokdad AH, Ford ES, Bowman BA, et al. Prevalence of obesity, diabetes, and obesity-related health risk factors, 2001. JAMA 289(1), 76-79 (2003). (Pubitemid 36026281)
2. Flegal KM, Carroll MD, Ogden CL, Curtin LR. Prevalence and trends in obesity among US adults, 1999-2008. JAMA 303(3), 235-241 (2010).
3. Wu T, Gao X, Chen M, Van Dam RM. Long-term effectiveness of diet-plus-exercise interventions vs. diet-only interventions for weight loss: a meta-analysis. Obes. Rev. 10(3), 313-323 (2009).
4. European Medicines Agency. Committee for Medicinal Products for Human Use. Guideline on clinical evaluation of medicinal products used in weight control (CPMP/EWP/281/96 Rev. 1). London, UK, 15 November 2007. Doc. Ref. EMEA/CHMP/EWP/517497/2007 (2007).
5. Rossner S, Sjostrom L, Noack R, Meinders AE, Noseda G. Weight loss, weight maintenance, and improved cardiovascular risk factors after 2 years treatment with orlistat for obesity. European Orlistat Obesity Study Group. Obes. Res. 8(1), 49-61 (2000).
6. Heymsfield SB, Segal KR, Hauptman J, et al. Effects of weight loss with orlistat on glucose tolerance and progression to Type 2 diabetes in obese adults. Arch. Intern. Med. 160(9), 1321-1326 (2000). (Pubitemid 30252779)
7. Torgerson JS, Hauptman J, Boldrin MN, Sjostrom L. XENical in the prevention of diabetes in obese subjects (XENDOS) study: a randomized study of orlistat as an adjunct to lifestyle changes for the prevention of Type 2 diabetes in obese patients. Diabetes Care 27(1), 155-161 (2004). (Pubitemid 38196725)
8. Field BC, Chaudhri OB, Bloom SR. Bowels control brain: gut hormones and obesity. Nat. Rev. Endocrinol. 6(8), 444-453 (2010).
9. Balthasar N, Dalgaard LT, Lee CE, et al. Divergence of melanocortin pathways in the control of food intake and energy expenditure. Cell 123(3), 493-505 (2005). (Pubitemid 41546678)
10. Gropp E, Shanabrough M, Borok E, et al. Agouti-related peptide-expressing neurons are mandatory for feeding. Nat. Neurosci. 8(10), 1289-1291 (2005). (Pubitemid 41630413)
11. Morton GJ, Cummings DE, Baskin DG, Barsh GS, Schwartz MW. Central nervous system control of food intake and body weight. Nature 443(7109), 289-295 (2006). (Pubitemid 44435142)
12. Keen-Rhinehart E, Bartness TJ. NPY Y1 receptor is involved in ghrelin- and fasting-induced increases in foraging, food hoarding, and food intake. Am. J. Physiol. Regul. Integr. Comp. Physiol. 292(4), R1728-R1737 (2007). (Pubitemid 46557800)
13. Berthoud HR, Morrison C. The brain, appetite, and obesity. Annu. Rev. Psychol. 59, 55-92 (2008).
14. Huszar D, Lynch CA, Fairchild-Huntress V, et al. Targeted disruption of the melanocortin-4 receptor results in obesity in mice. Cell 88(1), 131-141 (1997). (Pubitemid 27180337)
15. Farooqi S, ORahilly S. Genetics of obesity in humans. Endocr. Rev. 27(7), 710-718 (2006).
16. Krishna R, Gumbiner B, Stevens C, et al. Potent and selective agonism of the melanocortin receptor 4 with MK-0493 does not induce weight loss in obese human subjects: energy intake predicts lack of weight loss efficacy. Clin. Pharmacol. Ther. 86(6), 659-666 (2009).
17. Heisler LK, Jobst EE, Sutton GM, et al. Serotonin reciprocally regulates melanocortin neurons to modulate food intake. Neuron 51(2), 239-249 (2006). (Pubitemid 44063615)
18. Clifton PG, Kennett GA. Monoamine receptors in the regulation of feeding behaviour and energy balance. CNS Neurol. Disord. Drug Targets 5(3), 293-312 (2006). (Pubitemid 43881012)
19. Rolls BJ, Shide DJ, Thorwart ML, Ulbrecht JS. Sibutramine reduces food intake in non-dieting women with obesity. Obes. Res. 6(1), 1-11 (1998). (Pubitemid 128679638)
20. Barkeling B, Elfhag K, Rooth P, Rossner S. Short-term effects of sibutramine (Reductil) on appetite and eating behaviour and the long-term therapeutic outcome. Int. J. Obes. Relat. Metab. Disord. 27(6), 693-700 (2003). (Pubitemid 36712953)
21. James WP, Caterson ID, Coutinho W, et al. Effect of sibutramine on cardiovascular outcomes in overweight and obese subjects. N. Engl. J. Med. 363(10), 905-917 (2010).
22. Thatte U. NS-2330 (Neurosearch). Curr. Opin. Investig. Drugs 2(11), 1592-1594 (2001).
23. Astrup A, Meier DH, Mikkelsen BO, Villumsen JS, Larsen TM. Weight loss produced by tesofensine in patients with Parkinsons or Alzheimers disease. Obesity 16(6), 1363-1369 (2008). (Pubitemid 351770532)
24. Astrup A, Madsbad S, Breum L, Jensen TJ, Kroustrup JP, Larsen TM. Effect of tesofensine on bodyweight loss, body composition, and quality of life in obese patients: a randomised, double-blind, placebo-controlled trial. Lancet 372(9653), 1906-1913 (2008).
25. Lehr T, Staab A, Tillmann C, et al. Contribution of the active metabolite M1 to the pharmacological activity of tesofensine in vivo: a pharmacokinetic- pharmacodynamic modelling approach. Br. J. Pharmacol. 153(1), 164-174 (2008).
26. Nisoli E, Carruba MO. An assessment of the safety and efficacy of sibutramine, an anti-obesity drug with a novel mechanism of action. Obes. Rev. 1(2), 127-139 (2000).
27. Willett F, Curzen N, Adams J, Armitage M. Coronary vasospasm induced by subcutaneous sumatriptan. BMJ 304(6839), 1415 (1992).
28. Lloyd DK, Simmons V. Adverse reactions associated with sumatriptan. Lancet 341(8852), 1091-1092 (1993).
29. Ottervanger JP, Stricker BH. Sumatriptan and chest pain. Lancet 342(8864), 176 (1993).
30. Heal DJ, Smith SL, Fisas A, Codony X, Buschmann H. Selective 5-HT6 receptor ligands: progress in the development of a novel pharmacological approach to the treatment of obesity and related metabolic disorders. Pharmacol. Ther. 117(2), 207-231 (2008).
31. Fitzgerald LW, Burn TC, Brown BS, et al. Possible role of valvular serotonin 5-HT(2B) receptors in the cardiopathy associated with fenfluramine. Mol. Pharmacol. 57(1), 75-81 (2000). (Pubitemid 30033262)
32. Goodall EM, Cowen PJ, Franklin M, Silverstone T. Ritanserin attenuates anorectic, endocrine and thermic responses to d-fenfluramine in human volunteers. Psychopharmacology 112(4), 461-466 (1993). (Pubitemid 23324168)
33. Weintraub M, Hasday JD, Mushlin AI, Lockwood DH. A double-blind clinical trial in weight control. Use of fenfluramine and phentermine alone and in combination. Arch. Intern. Med. 144(6), 1143-1148 (1984). (Pubitemid 14121061)
34. Connolly HM, Crary JL, Mcgoon MD, et al. Valvular heart disease associated with fenfluramine-phentermine. N. Engl. J. Med. 337(9), 581-588 (1997). (Pubitemid 27360757)
35. Abenhaim L, Moride Y, Brenot F, et al. Appetite-suppressant drugs and the risk of primary pulmonary hypertension. International Primary Pulmonary Hypertension Study Group. N. Engl. J. Med. 335(9), 609-616 (1996). (Pubitemid 26277950)
36. Launay JM, Herve P, Peoch K, et al. Function of the serotonin 5-hydroxytryptamine 2B receptor in pulmonary hypertension. Nat. Med. 8(10), 1129-1135 (2002). (Pubitemid 35175968)
37. Rutz S, Riegert C, Rothmaier AK, Jackisch R. Presynaptic modulation of 5-HT release in the rat septal region. Neuroscience 146(2), 643-658 (2007). (Pubitemid 46629002)
38. Smith SR, Weissman NJ, Anderson CM, et al. Multicenter, placebo-controlled trial of lorcaserin for weight management. N. Engl. J. Med. 363(3), 245-256 (2010).
39. Erondu N, Gantz I, Musser B, et al. Neuropeptide Y5 receptor antagonism does not induce clinically meaningful weight loss in overweight and obese adults. Cell Metab. 4(4), 275-282 (2006). (Pubitemid 44430911)
40. Antal-Zimanyi I, Bruce MA, Leboulluec KL, et al. Pharmacological characterization and appetite suppressive properties of BMS-193885, a novel and selective neuropeptide Y(1) receptor antagonist. Eur. J. Pharmacol. 590(1-3), 224-232 (2008).
41. Chen X, Dimaggio DA, Han SP, Westfall TC. Autoreceptor-induced inhibition of neuropeptide Y release from PC-12 cells is mediated by Y2 receptors. Am. J. Physiol. 273(4 Pt 2), H1737-H1744 (1997).
42. Batterham RL, Cowley MA, Small CJ, et al. Gut hormone PYY(3-36) physiologically inhibits food intake. Nature 418(6898), 650-654 (2002).
43. Abbott CR, Monteiro M, Small CJ, et al. The inhibitory effects of peripheral administration of peptide YY(3-36) and glucagon-like peptide-1 on food intake are attenuated by ablation of the vagal- brainstem-hypothalamic pathway. Brain Res. 1044(1), 127-131 (2005). (Pubitemid 40616060)
44. Koda S, Takeda S, Onimaru H, Akada S, Sakamoto A. Cannabinoid suppressed bicuculline-induced convulsion without respiratory depression in the brainstem-spinal cord preparation from newborn rats. Biomed. Res. 26(6), 241-247 (2005). (Pubitemid 43137331)
45. Korner J, Inabnet W, Febres G, et al. Prospective study of gut hormone and metabolic changes after adjustable gastric banding and Roux-en-Y gastric bypass. Int. J. Obes. 33(7), 786-795 (2009).
46. Batterham RL, Cohen MA, Ellis SM, et al. Inhibition of food intake in obese subjects by peptide YY3-36. N. Engl. J. Med. 349(10), 941-948 (2003). (Pubitemid 37064767)
47. Degen L, Oesch S, Casanova M, et al. Effect of peptide YY3-36 on food intake in humans. Gastroenterology 129(5), 1430-1436 (2005). (Pubitemid 41597385)
48. Gantz I, Erondu N, Mallick M, et al. Efficacy and safety of intranasal peptide YY3-36 for weight reduction in obese adults. J. Clin. Endocrinol. Metab. 92(5), 1754-1757 (2007). (Pubitemid 46997183)
49. Le Roux CW, Borg CM, Murphy KG, Vincent RP, Ghatei MA, Bloom SR. Supraphysiological doses of intravenous PYY3-36 cause nausea, but no additional reduction in food intake. Ann. Clin. Biochem. 45(Pt 1), 93-95 (2008). (Pubitemid 351724622)
50. Dumont Y, Martel JC, Fournier A, St-Pierre S, Quirion R. Neuropeptide Y and neuropeptide Y receptor subtypes in brain and peripheral tissues. Prog. Neurobiol. 38(2), 125-167 (1992).
51. Flood JF, Morley JE. Dissociation of the effects of neuropeptide Y on feeding and memory: evidence for pre- and postsynaptic mediation. Peptides 10(5), 963-966 (1989). (Pubitemid 20003375)
52. Jacques D, Abdel-Samad D. Neuropeptide Y (NPY) and NPY receptors in the cardiovascular system: implication in the regulation of intracellular calcium. Can. J. Physiol. Pharmacol. 85(1), 43-53 (2007). (Pubitemid 46996103)
53. Merchenthaler I, Lane M, Shughrue P. Distribution of pre-pro-glucagon and glucagon-like peptide-1 receptor messenger RNAs in the rat central nervous system. J. Comp. Neurol. 403(2), 261-280 (1999). (Pubitemid 28566834)
54. Larsen PJ, Fledelius C, Knudsen LB, Tang-Christensen M. Systemic administration of the long-acting GLP-1 derivative NN2211 induces lasting and reversible weight loss in both normal and obese rats. Diabetes 50(11), 2530-2539 (2001). (Pubitemid 33642771)
55. Turton MD, OShea D, Gunn I, et al. A role for glucagon-like peptide-1 in the central regulation of feeding. Nature 379(6560), 69-72 (1996). (Pubitemid 26008136)
56. Tang-Christensen M, Larsen PJ, Goke R, et al. Central administration of GLP-1- (7-36) amide inhibits food and water intake in rats. Am. J. Physiol. 271(4 Pt 2), R848-R856 (1996).
57. Zander M, Madsbad S, Madsen JL, Holst JJ. Effect of 6-week course of glucagon-like peptide 1 on glycaemic control, insulin sensitivity, and b-cell function in Type 2 diabetes: a parallel-group study. Lancet 359(9309), 824-830 (2002). (Pubitemid 34233752)
58. Ratner RE, Maggs D, Nielsen LL, et al. Long-term effects of exenatide therapy over 82 weeks on glycaemic control and weight in over-weight metformin-treated patients with Type 2 diabetes mellitus. Diabetes Obes. Metab. 8(4), 419-428 (2006). (Pubitemid 44349234)
59. Riddle MC, Henry RR, Poon TH, et al. Exenatide elicits sustained glycaemic control and progressive reduction of body weight in patients with Type 2 diabetes inadequately controlled by sulphonylureas with or without metformin. Diabetes Metab. Res. Rev. 22(6), 483-491 (2006). (Pubitemid 44774053)
60. Buse JB, Henry RR, Han J, Kim DD, Fineman MS, Baron AD. Effects of exenatide (exendin-4) on glycemic control over 30 weeks in sulfonylurea-treated patients with Type 2 diabetes. Diabetes Care 27(11), 2628-2635 (2004). (Pubitemid 39441462)
61. Defronzo RA, Ratner RE, Han J, Kim DD, Fineman MS, Baron AD. Effects of exenatide (exendin-4) on glycemic control and weight over 30 weeks in metformin-treated patients with Type 2 diabetes. Diabetes Care 28(5), 1092-1100 (2005). (Pubitemid 40616618)
62. Nauck M, Frid A, Hermansen K, et al. Efficacy and safety comparison of liraglutide, glimepiride, and placebo, all in combination with metformin, in Type 2 diabetes: the LEAD (liraglutide effect and action in diabetes)-2 study. Diabetes Care 32(1), 84-90 (2009).
63. Zinman B, Gerich J, Buse JB, et al. Efficacy and safety of the human glucagon-like peptide-1 analog liraglutide in combination with metformin and thiazolidinedione in patients with Type 2 diabetes (LEAD-4 Met+TZD). Diabetes Care 32(7), 1224-1230 (2009).
64. Garber A, Henry R, Ratner R, et al. Liraglutide versus glimepiride monotherapy for Type 2 diabetes (LEAD-3 Mono): a randomised, 52-week, phase III, double-blind, parallel-treatment trial. Lancet 373(9662), 473-481 (2009).
65. Drucker DJ, Buse JB, Taylor K, et al. Exenatide once weekly versus twice daily for the treatment of Type 2 diabetes: a randomised, open-label, non-inferiority study. Lancet 372(9645), 1240-1250 (2008).
66. Diamant M, Van Gaal L, Stranks S, et al. Once weekly exenatide compared with insulin glargine titrated to target in patients with Type 2 diabetes (DURATION-3): an open-label randomised trial. Lancet 375(9733), 2234-2243 (2010).
67. Skyler JS, Bergenstal R, Bonow RO, et al. Intensive glycemic control and the prevention of cardiovascular events: implications of the ACCORD, ADVANCE, and VA diabetes trials: a position statement of the American Diabetes Association and a scientific statement of the American College of Cardiology Foundation and the American Heart Association. Circulation 119(2), 351-357 (2009).
68. Bergenstal RWC, Yan P, Macconell L, Malloy J, Porter L. DURATION-2: exenatide once weekly demonstrated superior glycemic control and weight reduction compared with sitagliptin or pioglitazone after 26 weeks of treatment. Presented at: American Diabetes Association 2009 Scientific Sessions. New Orleans, LA, USA, 7 June 2009.
69. Sebokova E, Benardeau A, Sprecher U, Sewing S, Tobalina L, Migliorini C. Taspoglutide, a novel human once-weekly analogue of glucagon-like peptide-1, improves glucose homeostasis and body weight in the Zucker diabetic fatty rat. Diabetes Obes. Metab. 12(8), 674-682 (2010).
70. Ratner R, Nauck M, Kapitza C, Asnaghi V, Boldrin M, Balena R. Safety and tolerability of high doses of taspoglutide, a once-weekly human GLP-1 analogue, in diabetic patients treated with metformin: a randomized double-blind placebo-controlled study. Diabet. Med. 27(5), 556-562 (2010).
71. Kolterman OG, Kim DD, Shen L, et al. Pharmacokinetics, pharmacodynamics, and safety of exenatide in patients with Type 2 diabetes mellitus. Am. J. Health Syst. Pharm. 62(2), 173-181 (2005). (Pubitemid 40674548)
72. Astrup A, Rossner S, Van Gaal L, et al. Effects of liraglutide in the treatment of obesity: a randomised, double-blind, placebo-controlled study. Lancet 374(9701), 1606-1616 (2009).
73. Byetta® package insert. Amylin Pharmaceuticals, Inc., San Diego, CA, USA (2007).
74. Bjerre Knudsen L, Madsen LW, Andersen S, et al. Glucagon-like peptide-1 receptor agonists activate rodent thyroid C-cells causing calcitonin release and C-cell proliferation. Endocrinology 151(4), 1473-1486 (2010).
75. Parks M, Rosebraugh C. Weighing risks and benefits of liraglutide - the FDAs review of a new antidiabetic therapy. N. Engl. J. Med. 362(9), 774-777 (2010).
76. Victoza® (liraglutide [rDNA origin] injection) Prescribing Information. Novo Nordisk A/S, Princeton, NJ, USA (2011).
77. Baggio LL, Huang Q, Brown TJ, Drucker DJ. Oxyntomodulin and glucagon-like peptide-1 differentially regulate murine food intake and energy expenditure. Gastroenterology 127(2), 546-558 (2004). (Pubitemid 39091903)
78. Dakin CL, Gunn I, Small CJ, et al. Oxyntomodulin inhibits food intake in the rat. Endocrinology 142(10), 4244-4250 (2001). (Pubitemid 32907050)
79. Dakin CL, Small CJ, Park AJ, Seth A, Ghatei MA, Bloom SR. Repeated ICV administration of oxyntomodulin causes a greater reduction in body weight gain than in pair-fed rats. Am. J. Physiol. Endocrinol. Metab. 283(6), E1173-E1177 (2002). (Pubitemid 35340623)
80. Dakin CL, Small CJ, Batterham RL, et al. Peripheral oxyntomodulin reduces food intake and body weight gain in rats. Endocrinology 145(6), 2687-2695 (2004). (Pubitemid 38686215)
81. Cohen MA, Ellis SM, Le Roux CW, et al. Oxyntomodulin suppresses appetite and reduces food intake in humans. J. Clin. Endocrinol. Metab. 88(10), 4696-4701 (2003). (Pubitemid 37357514)
82. Wynne K, Park AJ, Small CJ, et al. Subcutaneous oxyntomodulin reduces body weight in overweight and obese subjects: a double-blind, randomized, controlled trial. Diabetes 54(8), 2390-2395 (2005). (Pubitemid 41134267)
83. Wynne K, Park AJ, Small CJ, et al. Oxyntomodulin increases energy expenditure in addition to decreasing energy intake in overweight and obese humans: a randomised controlled trial. Int. J. Obes. 30(12), 1729-1736 (2006). (Pubitemid 44863404)
84. Kerr BD, Flatt PR, Gault VA. (D-Ser2) Oxm[mPEG-PAL]: a novel chemically modified analogue of oxyntomodulin with antihyperglycaemic, insulinotropic and anorexigenic actions. Biochem. Pharmacol. 80(11), 1727-1735 (2010).
85. Kenny PJ. Reward mechanisms in obesity: new insights and future directions. Neuron 69(4), 664-679 (2011).
86. Jamshidi N, Taylor DA. Anandamide administration into the ventromedial hypothalamus stimulates appetite in rats. Br. J. Pharmacol. 134(6), 1151-1154 (2001). (Pubitemid 33097243)
87. Kirkham TC, Williams CM, Fezza F, Di Marzo V. Endocannabinoid levels in rat limbic forebrain and hypothalamus in relation to fasting, feeding and satiation: stimulation of eating by 2-arachidonoyl glycerol. Br. J. Pharmacol. 136(4), 550-557 (2002). (Pubitemid 34717699)
88. Van Gaal LF, Rissanen AM, Scheen AJ, Ziegler O, Rossner S. Effects of the cannabinoid-1 receptor blocker rimonabant on weight reduction and cardiovascular risk factors in overweight patients: 1-year experience from the RIO-Europe study. Lancet 365(9468), 1389-1397 (2005). (Pubitemid 40523733)
89. Scheen AJ, Finer N, Hollander P, Jensen MD, Van Gaal LF. Efficacy and tolerability of rimonabant in overweight or obese patients with Type 2 diabetes: a randomised controlled study. Lancet 368(9548), 1660-1672 (2006). (Pubitemid 46048528)
90. Pi-Sunyer FX, Aronne LJ, Heshmati HM, Devin J, Rosenstock J. Effect of rimonabant, a cannabinoid-1 receptor blocker, on weight and cardiometabolic risk factors in overweight or obese patients: RIO-North America: a randomized controlled trial. JAMA 295(7), 761-775 (2006). (Pubitemid 43244304)
91. Blundell JE. Perspective on the central control of appetite. Obesity 14(Suppl. 4), 160S-163S (2006).
92. Van Gaal LF, Scheen AJ, Rissanen AM, Rossner S, Hanotin C, Ziegler O. Long-term effect of CB1 blockade with rimonabant on cardiometabolic risk factors: two year results from the RIO-Europe Study. Eur. Heart J. 29(14), 1761-1771 (2008). (Pubitemid 352019811)
93. Addy C, Wright H, Van Laere K, et al. The acyclic CB1R inverse agonist taranabant mediates weight loss by increasing energy expenditure and decreasing caloric intake. Cell Metab. 7(1), 68-78 (2008).
94. Addy C, Li S, Agrawal N, et al. Safety, tolerability, pharmacokinetics, and pharmacodynamic properties of taranabant, a novel selective cannabinoid-1 receptor inverse agonist, for the treatment of obesity: results from a double-blind, placebo-controlled, single oral dose study in healthy volunteers. J. Clin. Pharmacol. 48(4), 418-427 (2008). (Pubitemid 351389116)
95. Addy C, Rothenberg P, Li S, et al. Multiple-dose pharmacokinetics, pharmacodynamics, and safety of taranabant, a novel selective cannabinoid-1 receptor inverse agonist, in healthy male volunteers. J. Clin. Pharmacol. 48(6), 734-744 (2008). (Pubitemid 351713158)
96. Aronne LJ, Tonstad S, Moreno M, et al. A clinical trial assessing the safety and efficacy of taranabant, a CB1R inverse agonist, in obese and overweight patients: a high-dose study. Int. J. Obes. 34(5), 919-935 (2010).
97. Proietto J, Rissanen A, Harp JB, et al. A clinical trial assessing the safety and efficacy of the CB1R inverse agonist taranabant in obese and overweight patients: low-dose study. Int. J. Obes. 34(8), 1243-1254 (2010).
98. Kipnes MS, Hollander P, Fujioka K, et al. A one-year study to assess the safety and efficacy of the CB1R inverse agonist taranabant in overweight and obese patients with Type 2 diabetes. Diabetes Obes. Metab. 12(6), 517-531 (2010).
99. Gadde KM, Franciscy DM, Wagner HR 2nd, Krishnan KR. Zonisamide for weight loss in obese adults: a randomized controlled trial. JAMA 289(14), 1820-1825 (2003). (Pubitemid 37430252)
100. Van Ameringen M, Mancini C, Pipe B, Campbell M, Oakman J. Topiramate treatment for SSRI-induced weight gain in anxiety disorders. J. Clin. Psychiatry 63(11), 981-984 (2002). (Pubitemid 35388055)
101. Bray GA, Hollander P, Klein S, et al. A 6-month randomized, placebo-controlled, dose-ranging trial of topiramate for weight loss in obesity. Obes. Res. 11(6), 722-733 (2003). (Pubitemid 41151598)
102. Zernig G, De Wit H, Telser S, et al. Subjective effects of slow-release bupropion versus caffeine as determined in a quasi-naturalistic setting. Pharmacology 70(4), 206-215 (2004). (Pubitemid 38316491)
103. Okada M, Kaneko S, Hirano T, et al. Effects of zonisamide on dopaminergic system. Epilepsy Res. 22(3), 193-205 (1995).
104. Okada M, Hirano T, Kawata Y, et al. Biphasic effects of zonisamide on serotonergic system in rat hippocampus. Epilepsy Res. 34(2-3), 187-197 (1999). (Pubitemid 29155490)
105. Gadde KM, Yonish GM, Foust MS, Wagner HR. Combination therapy of zonisamide and bupropion for weight reduction in obese women: a preliminary, randomized, open-label study. J. Clin. Psychiatry 68(8), 1226-1229 (2007). (Pubitemid 47395625)
106. Roose SP, Dalack GW, Glassman AH, Woodring S, Walsh BT, Giardina EG. Cardiovascular effects of bupropion in depressed patients with heart disease. Am. J. Psychiatry 148(4), 512-516 (1991).
107. Aubin HJ. Tolerability and safety of sustained-release bupropion in the management of smoking cessation. Drugs 62(Suppl. 2), 45-52 (2002).
108. Mula M, Sander JW. Negative effects of antiepileptic drugs on mood in patients with epilepsy. Drug Saf. 30(7), 555-567 (2007). (Pubitemid 47037315)
109. Ohtahara S, Yamatogi Y. Safety of zonisamide therapy: prospective follow-up survey. Seizure 13(Suppl. 1), S50-S55; discussion S56 (2004). (Pubitemid 39420024)
110. Greenway FL, Whitehouse MJ, Guttadauria M, et al. Rational design of a combination medication for the treatment of obesity. Obesity 17(1), 30-39 (2009). (Pubitemid 50324544)
111. Wadden TA, Foreyt JP, Foster GD, et al. Weight loss with naltrexone SR/bupropion SR combination therapy as an adjunct to behavior modification: the COR-BMOD trial. Obesity 19(1), 110-120 (2011).
112. Smith SR. Naltrexone-buproprion causes weight loss in overweight and obese adults. Evid. Based Med. 16(2), 53-54 (2011).
113. Greenway FL, Fujioka K, Plodkowski RA, et al. Effect of naltrexone plus bupropion on weight loss in overweight and obese adults (COR-I): a multicentre, randomised, double-blind, placebo-controlled, Phase 3 trial. Lancet 376(9741), 595-605 (2010).
114. Gomez R, Navarro M, Ferrer B, et al. A peripheral mechanism for CB1 cannabinoid receptor-dependent modulation of feeding. J. Neurosci. 22(21), 9612-9617 (2002). (Pubitemid 35356203)
115. Nogueiras R, Veyrat-Durebex C, Suchanek PM, et al. Peripheral, but not central, CB1 antagonism provides food intake-independent metabolic benefits in diet-induced obese rats. Diabetes 57(11), 2977-2991 (2008).
116. Randall PA, Vemuri VK, Segovia KN, et al. The novel cannabinoid CB1 antagonist AM6545 suppresses food intake and food-reinforced behavior. Pharmacol. Biochem. Behav. 97(1), 179-184 (2010).
117. Aronne L, Fujioka K, Aroda V, et al. Progressive reduction in body weight after treatment with the amylin analog pramlintide in obese subjects: a Phase 2, randomized, placebo-controlled, dose-escalation study. J. Clin. Endocrinol. Metab. 92(8), 2977-2983 (2007). (Pubitemid 47236359)
118. Smith SR, Aronne LJ, Burns CM, Kesty NC, Halseth AE, Weyer C. Sustained weight loss following 12-month pramlintide treatment as an adjunct to lifestyle intervention in obesity. Diabetes Care 31(9), 1816-1823 (2008).
119. Mack CM, Soares CJ, Wilson JK, et al. Davalintide (AC2307), a novel amylin-mimetic peptide: enhanced pharmacological properties over native amylin to reduce food intake and body weight. Int. J. Obes. 34(2), 385-395 (2010).
120. Ravussin E, Smith SR, Mitchell JA, et al. Enhanced weight loss with pramlintide/metreleptin: an integrated neurohormonal approach to obesity pharmacotherapy. Obesity 17(9), 1736-1743 (2009).
121. Symlin® (pramlintide acetate) injection. Prescribing Information. Amylin Pharmaceuticals Inc., CA, USA (2005).
122. Whitehouse F, Kruger DF, Fineman M, et al. A randomized study and open-label extension evaluating the long-term efficacy of pramlintide as an adjunct to insulin therapy in Type 1 diabetes. Diabetes Care 25(4), 724-730 (2002). (Pubitemid 41071194)
123. Hollander PA, Levy P, Fineman MS, et al. Pramlintide as an adjunct to insulin therapy improves long-term glycemic and weight control in patients with Type 2 diabetes: a 1-year randomized controlled trial. Diabetes Care 26(3), 784-790 (2003). (Pubitemid 36929344)
124. Ratner RE, Want LL, Fineman MS, et al. Adjunctive therapy with the amylin analogue pramlintide leads to a combined improvement in glycemic and weight control in insulin-treated subjects with Type 2 diabetes. Diabetes Technol. Ther. 4(1), 51-61 (2002). (Pubitemid 34441520)
125. Ratner RE, Dickey R, Fineman M, et al. Amylin replacement with pramlintide as an adjunct to insulin therapy improves long-term glycaemic and weight control in Type 1 diabetes mellitus: a 1-year, randomized controlled trial. Diabet. Med. 21(11), 1204-1212 (2004). (Pubitemid 39472376)
126. Edelman S, Garg S, Frias J, et al. A double-blind, placebo-controlled trial assessing pramlintide treatment in the setting of intensive insulin therapy in type 1 diabetes. Diabetes Care 29(10), 2189-2195 (2006). (Pubitemid 44899850)
127. Karl D, Philis-Tsimikas A, Darsow T, et al. Pramlintide as an adjunct to insulin in patients with Type 2 diabetes in a clinical practice setting reduced A1C, postprandial glucose excursions, and weight. Diabetes Technol. Ther. 9(2), 191-199 (2007). (Pubitemid 46652555)
128. Minokoshi Y, Alquier T, Furukawa N, et al. AMP-kinase regulates food intake by responding to hormonal and nutrient signals in the hypothalamus. Nature 428(6982), 569-574 (2004). (Pubitemid 38480541)
129. Bergeron R, Russell RR 3rd, Young LH, et al. Effect of AMPK activation on muscle glucose metabolism in conscious rats. Am. J. Physiol. 276(5 Pt 1), E938-E944 (1999). (Pubitemid 29249614)
130. Merrill GF, Kurth EJ, Hardie DG, Winder WW. AICA riboside increases AMP-activated protein kinase, fatty acid oxidation, and glucose uptake in rat muscle. Am. J. Physiol. 273(6 Pt 1), E1107-E1112 (1997).
131. Salt IP, Connell JM, Gould GW. 5-aminoimidazole-4-carboxamide ribonucleoside (AICAR) inhibits insulin-stimulated glucose transport in 3T3-L1 adipocytes. Diabetes 49(10), 1649-1656 (2000).
132. Andersson U, Filipsson K, Abbott CR, et al. AMP-activated protein kinase plays a role in the control of food intake. J. Biol. Chem. 279(13), 12005-12008 (2004). (Pubitemid 38445761)
133. Chakrabarti R, Misra P, Vikramadithyan RK, et al. Antidiabetic and hypolipidemic potential of DRF 2519 - a dual activator of PPAR-aand PPAR-g. Eur. J. Pharmacol. 491(2-3), 195-206 (2004). (Pubitemid 38609478)
134. Jones JR, Barrick C, Kim KA, et al. Deletion of PPARg in adipose tissues of mice protects against high fat diet-induced obesity and insulin resistance. Proc. Natl Acad. Sci. USA 102(17), 6207-6212 (2005). (Pubitemid 40594279)
135. Doggrell S. Do peroxisome proliferation receptor-g antagonists have clinical potential as combined antiobesity and antidiabetic drugs? Expert Opin. Investig. Drugs 12(4), 713-716 (2003). (Pubitemid 36512014)
136. Oberfield JL, Collins JL, Holmes CP, et al. A peroxisome proliferator-activated receptor g ligand inhibits adipocyte differentiation. Proc. Natl Acad. Sci. USA 96(11), 6102-6106 (1999). (Pubitemid 29256626)
137. Mukherjee R, Hoener PA, Jow L, et al. A selective peroxisome proliferator-activated receptor-g (PPARg) modulator blocks adipocyte differentiation but stimulates glucose uptake in 3T3-L1 adipocytes. Mol. Endocrinol. 14(9), 1425-1433 (2000).
138. Drucker DJ, Nauck MA. The incretin system: glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors in Type 2 diabetes. Lancet 368(9548), 1696-1705 (2006). (Pubitemid 46048557)
139. Ahren B. Islet G protein-coupled receptors as potential targets for treatment of Type 2 diabetes. Nat. Rev. Drug Discov. 8(5), 369-385 (2009).
140. Chu ZL, Jones RM, He H, et al. A role for b-cell-expressed G protein-coupled receptor 119 in glycemic control by enhancing glucose-dependent insulin release. Endocrinology 148(6), 2601-2609 (2007). (Pubitemid 46984798)
141. Lauffer LM, Iakoubov R, Brubaker PL. GPR119 is essential for oleoylethanolamide-induced glucagon-like peptide-1 secretion from the intestinal enteroendocrine L-cell. Diabetes 58(5), 1058-1066 (2009).
142. Ning Y, Oneill K, Lan H, et al. Endogenous and synthetic agonists of GPR119 differ in signalling pathways and their effects on insulin secretion in MIN6c4 insulinoma cells. Br. J. Pharmacol. 155(7), 1056-1065 (2008).
143. Overton HA, Fyfe MC, Reynet C. GPR119, a novel G protein-coupled receptor target for the treatment of Type 2 diabetes and obesity. Br. J. Pharmacol. 153(Suppl. 1), S76-S81 (2008). (Pubitemid 351340991)
144. Semple G, Fioravanti B, Pereira G, et al. Discovery of the first potent and orally efficacious agonist of the orphan G-protein coupled receptor 119. J. Med. Chem. 51(17), 5172-5175 (2008).
145. Chu ZL, Carroll C, Alfonso J, et al. A role for intestinal endocrine cell-expressed g protein-coupled receptor 119 in glycemic control by enhancing glucagon-like peptide-1 and glucose-dependent insulinotropic peptide release. Endocrinology 149(5), 2038-2047 (2008). (Pubitemid 351574507)
146. Lan H, Vassileva G, Corona A, et al. Mice lacking GPR119 maintain metabolic homeostasis. Presented at: Keystone Symposium. Diabetes: Molecular Genetics, Signalling Pathways and Integrated Physiology 2007. Keystone, CO, USA, 14-19 January 2007.
147. Nomura S, Sakamaki S, Hongu M, et al. Discovery of canagliflozin, a novel C-glucoside with thiophene ring, as sodium-dependent glucose cotransporter 2 inhibitor for the treatment of Type 2 diabetes mellitus. J. Med. Chem. 53(17), 6355-6360 (2010).
148. Han S, Hagan DL, Taylor JR, et al. Dapagliflozin, a selective SGLT2 inhibitor, improves glucose homeostasis in normal and diabetic rats. Diabetes 57(6), 1723-1729 (2008).
149. Meng W, Ellsworth BA, Nirschl AA, et al. Discovery of dapagliflozin: a potent, selective renal sodium-dependent glucose cotransporter 2 (SGLT2) inhibitor for the treatment of Type 2 diabetes. J. Med. Chem. 51(5), 1145-1149 (2008). (Pubitemid 351480378)
150. Komoroski B, Vachharajani N, Feng Y, Li L, Kornhauser D, Pfister M. Dapagliflozin, a novel, selective SGLT2 inhibitor, improved glycemic control over 2 weeks in patients with Type 2 diabetes mellitus. Clin. Pharmacol. Ther. 85(5), 513-519 (2009).
151. List JF, Woo V, Morales E, Tang W, Fiedorek FT. Sodium-glucose cotransport inhibition with dapagliflozin in Type 2 diabetes. Diabetes Care 32(4), 650-657 (2009).
152. Bailey CJ, Gross JL, Pieters A, Bastien A, List JF. Effect of dapagliflozin in patients with Type 2 diabetes who have inadequate glycaemic control with metformin: a randomised, double-blind, placebo-controlled trial. Lancet 375(9733), 2223-2233 (2010).
153. Strojek K. Efficacy and safety of dapagliflozin in patients with Type 2 diabetes mellitus and inadequate glycaemic control on glimperide monotherapy. Abstract 870. Presented at: 46th Annual Meeting of the European Association for the Study of Diabetes (EASD). Stockholm, Sweden, 20-24 September 2010 (Abstract 870).
154. Wilding JP, Norwood P, Tjoen C, Bastien A, List JF, Fiedorek FT. A study of dapagliflozin in patients with Type 2 diabetes receiving high doses of insulin plus insulin sensitizers: applicability of a novel insulin-independent treatment. Diabetes Care 32(9), 1656-1662 (2009).
155. Bays HE. Lorcaserin and adiposopathy: 5-HT2c agonism as a treatment for sick fat and metabolic disease. Expert Rev. Cardiovasc. Ther. 7(11), 1429-1445 (2009).
156. Sjostrom L, Narbro K, Sjostrom CD, et al. Effects of bariatric surgery on mortality in Swedish obese subjects. N. Engl. J. Med. 357(8), 741-752 (2007). (Pubitemid 47295641)
157. Cummings DE, Overduin J, Foster-Schubert KE. Gastric bypass for obesity: mechanisms of weight loss and diabetes resolution. J. Clin. Endocrinol. Metab. 89(6), 2608-2615 (2004). (Pubitemid 38766339)
158. Cummings DE, Shannon MH. Roles for ghrelin in the regulation of appetite and body weight. Arch. Surg. 138(4), 389-396 (2003). (Pubitemid 36417676)
159. Vincent RP, Le Roux CW. The satiety hormone peptide YY as a regulator of appetite. J. Clin. Pathol. 61(5), 548-552 (2008). (Pubitemid 351678205)
160. Le Roux CW, Welbourn R, Werling M, et al. Gut hormones as mediators of appetite and weight loss after Roux-en-Y gastric bypass. Ann. Surg. 246(5), 780-785 (2007). (Pubitemid 350035654)
161. WHO. Obesity and overweight www.who.int/mediacentre/factsheets/fs311/en/ index.html
162. NHS. Statistics on obesity, physical activity and diet, England 2006 www.ic.nhs.uk/statistics-and-data-collections/health-and-lifestyles/obesity/ statistics-on-obesity-physical-activity-and-diet-england-2006
163. Public Citizen. Comments on FDA Obesity Trial Guidelines www.citizen.org/page.aspx?pid=742
164. Safety alerts for human medical products: Orlistat (marketed as Alli and Xenical): Labeling Change www.fda.gov/safety/medwatch/safetyinformation/ safetyalertsforhumanmedicalproducts/ucm213448.htm
165. New York Times - Abbott Labs Withdraw Meridia from the Market www.nytimes.com/2010/10/09/health/09drug.html?ref=business
166. PR Newswire - FDA Issues Complete Response Letter for Lorcaserin New Drug Application www.prnewswire.com/news-releases/fda-issues-complete-response- letter-for-lorcaserin-new-drug-application- 105586113.html
167. Roche pipeline www.roche.com/research-and-development/pipeline.htm
168. Clinicaltrials.gov: A Study With RO5095932 in Patients With Type 2 Diabetes on Stable Metformin Therapy http://clinicaltrials.gov/ct2/show/ NCT01017302
169. NeLM news service: FDA panel votes against approving rimonabant for obesity in the United States www.nelm.nhs.uk/en/NeLM-Area/News/490986/491126/ 491138
170. VIVUS: Qnexa meets primary endpoint by demonstrating superior weight loss over components and placebo in the 28-week equate study (OB-301) http://ir.vivus.com/releasedetail. cfm?releaseid=353965
171. VIVUS Inc. Press releases (2010) http://ir.vivus.com/releases.cfm?year= &releasestype=&pagenum=2
172. VIVUS announces positive results from two Phase 3 studies; obese patients on Qnexa achieve average weight loss up to 14.7% and significant improvements in co-morbidities http://ir.vivus.com/releasedetail. cfm?releaseid=407933
173. Orexigen Therapeutics, Inc. Press Release. Orexigen® Therapeutics Phase 2b Trial for Empatic™ Meets Primary Efficacy Endpoint Demonstrating Significantly Greater Weight Loss Versus Comparators in Obese Patients http://ir.orexigen.Com/Phoenix. Zhtml?C=207034&P=Irol- Newsarticle&Id= 1336796&Highlight
174. ZYBAN® (bupropion hydrochloride) sustained-release tablets www.biopsychiatry.com/bupropion/bupropion-zyban.pdf
175. Orexigen Therapeutics, Inc. Press Release. Orexigen® Therapeutics Investigational Drug Contrave® Receives Positive Recommendation from FDA Advisory Committee for Treatment of Obesity http://ir.orexigen.com/phoenix. zhtml?c=207034&p=irol-newsArticle&ID=1505602&highlight
176. Fierce Biotech: Orexigen crashes after FDA demands pre-approval Contrave study www.fiercebiotech.com/story/orexigen-crashes-after-fda-demands-pre- approval-contrave-study/2011-02-01?utm-medium=nl&utm-source=internal
177. 7TM Pharma: TM38837 www.7tm.com/r-d/metabolic-disorders/tm38837.aspx